Conference
Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A
Abstract
Background
Damoctocog alfa pegol (BAY 94-9027; Jivi®) is a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated with a single, dual-branched 60 kDa polyethylene glycol molecule to extend its half-life. A previous head-to-head crossover study demonstrated that damoctocog alfa pegol has an improved pharmacokinetic (PK) profile compared with efmoroctocog alfa (rFVIIIFc; Elocta®/Eloctate®), an …
Authors
Solms A; Shah A; Wiegmann S; Ahsman M; Berntorp E; Tiede A; Iorio A; Mancuso ME; Zhivkov T; Lissitchkov T
Volume
136
Pagination
pp. 24-25
Publisher
American Society of Hematology
Publication Date
November 5, 2020
DOI
10.1182/blood-2020-136586
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971